615 terminations of pregnancy have been performed in Oxford over a 3-year period with @entity2918 as the prime abortifacient agent; an intravenous infusion of @entity398 was used in 50% of cases. The routes of administration and dose regimen were intraamniotic, extraamniotic, and intravenous. 7 @entity1 had a history of @entity302 and were receiving anticonvulsant therapy at the time of admission for termination; this was continued during the abortion procedure. 1 of these @entity1 had fits after admission (but before therapy) and after abortion, but none of the 615 @entity1 had @entity410 during the administration of the @entity2918 . 6 of the @entity302 group received @entity1421 extraamniotically, and the 7th @entity1 @entity1421 intraamniotically. Abortion occurred between 7 and 35-1/2 hours. A WHO report quotes trials in 2 university centers of 123 @entity1 treated with intraamniotic PGF2 alpha and 126 @entity1 given intraamniotic hypertonic saline assigned to treatment by random allocation. @entity410 occurred in 1 @entity1 in each group: their previous history is unrecorded. The @entity410 reported by Lyneham et al. occurred 7-30 hours after instillation of @entity2918 , which probably precludes the possibility of accidental systemic administration, but which may suggest the involvement of circulating metabolites or endogenous production triggered by abortion processes.

Letter: XXXX and prostaglandin-induced abortion.

@entity398 :: ('MESH:D010121', 'Chemical') :: ['oxytocin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity410 :: ('MESH:D012640', 'Disease') :: ['Convulsions', 'convulsions'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2'] @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizures', 'epileptic']
@entity410 :: (MESH:D012640,Disease) :: ['Convulsions']
